Recent Updates
Recently added Catalysts

Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody

Phase 1

Systemic Sclerosis | Small molecule | Immunology |Sanofi|Last Updated: Mar 5, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody · 1 trial · 2 indications

Phase 1 1
NCT00043706Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic SclerosisSystemic Sclerosis
COMPLETED- Analytics
PHASE1COMPLETED
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Systemic Sclerosis
NCT00043706-
Unlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
Human Anti-Transforming Growth Factor Beta-1 Monoclonal AntibodyDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Diagnosis of diffuse systemic sclerosis * Duration of disease 18 months or less * Modified Rodnan Skin Score in a range as identified by the study protocol * Evidence of worsening disease activity * Ability to attend follow-up assessments for a minimum of 9 months * Agree to d...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Systemic Sclerosis 29 trials

Top 20 of 21 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN2PHASE3Anifrolumab
Bristol-Myers Squibb CompanyBMY2PHASE3BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab
Merck & Co., Inc.MRK1PHASE2Tulisokibart
Novartis AG Sponsored ADRNVS2PHASE2rapcabtagene autoleucel, rituximab
GSK plc Sponsored ADRGSK1PHASE2Belimumab
argenx SE Sponsored ADRARGX1PHASE2Efgartigimod PH20
Cumberland Pharmaceuticals Inc.CPIX1PHASE2Ifetroban
Zura Bio Limited Class AZURA1PHASE2Tibulizumab
Cabaletta Bio, Inc.CABA1PHASE2CABA-201
Artiva Biotherapeutics, Inc.ARTV1PHASE2Allogeneic NK Cells
Gilead Sciences, Inc.GILD1PHASE1KITE-363, Fludarabine, Cyclophosphamide
Kyverna Therapeutics, Inc.KYTX2PHASE1KYV-101, Cyclophosphamide, Fludarabine
CRISPR Therapeutics AGCRSP1PHASE1CTX112
Fate Therapeutics, Inc.FATE1PHASE1FT819, Fludarabine, Cyclophosphamide, Bendamustine
Nkarta, Inc.NKTX1PHASE1NKX019, Fludarabine, Cyclophosphamide
Adicet Bio IncACET1PHASE1ADI-001, Fludarabine, Cyclophosphamide
Allogene Therapeutics, Inc.ALLO1PHASE1ALLO-329, Cyclophosphamide, Fludarabine
Century Therapeutics, Inc.IPSC1PHASE1CNTY-101, IL-2, Lymphodepleting Chemotherapy
Precision BioSciences, Inc.DTIL2PHASE1BCMA/CD70-targetd CAR-T
TScan Therapeutics, Inc.TCRX1 - Undisclosed
Unlock Competitive Intelligence